Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care

Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care

Adoptive cell therapy (ACT) with tumor-infiltrating T cells (TILs) has emerged as a promising therapy for the treatment of unresectable or metastatic solid tumors. One challenge to finding a universal anticancer treatment is the heterogeneity present between different tumors as a result of genetic i...

Full description

Bibliographic Details
Main Authors: Shuyang S. Qin, Alexa D. Melucci, Alexander C. Chacon, Peter A. Prieto
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cells
Subjects:
adoptive cell therapy
tumor-infiltrating T cells
immunotherapy
metastatic treatment
Online Access:https://www.mdpi.com/2073-4409/10/4/808
id doaj-d9dacc9ffee547b88ae15ffeeb741347
record_format Article
spelling doaj-d9dacc9ffee547b88ae15ffeeb7413472021-04-05T23:00:45ZengMDPI AGCells2073-44092021-04-011080880810.3390/cells10040808Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of CareShuyang S. Qin0Alexa D. Melucci1Alexander C. Chacon2Peter A. Prieto3Department of Microbiology & Immunology, University of Rochester School of Medicine & Dentistry, Rochester, NY 14642, USADepartment of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USADepartment of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USADepartment of Surgery, University of Rochester Medical Center, Rochester, NY 14642, USAAdoptive cell therapy (ACT) with tumor-infiltrating T cells (TILs) has emerged as a promising therapy for the treatment of unresectable or metastatic solid tumors. One challenge to finding a universal anticancer treatment is the heterogeneity present between different tumors as a result of genetic instability associated with tumorigenesis. As the epitome of personalized medicine, TIL-ACT bypasses the issue of intertumoral heterogeneity by utilizing the patient’s existing antitumor immune response. Despite being one of the few therapies capable of inducing durable, complete tumor regression, many patients fail to respond. Recent research has focused on increasing therapeutic efficacy by refining various aspects of the TIL protocol, which includes the isolation, ex vivo expansion, and subsequent infusion of tumor specific lymphocytes. This review will explore how the therapy has evolved with time by highlighting various resistance mechanisms to TIL therapy and the novel strategies to overcome them.https://www.mdpi.com/2073-4409/10/4/808adoptive cell therapytumor-infiltrating T cellsimmunotherapymetastatic treatment
collection DOAJ
language English
format Article
sources DOAJ
author Shuyang S. Qin
Alexa D. Melucci
Alexander C. Chacon
Peter A. Prieto
spellingShingle Shuyang S. Qin
Alexa D. Melucci
Alexander C. Chacon
Peter A. Prieto
Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care
Cells
adoptive cell therapy
tumor-infiltrating T cells
immunotherapy
metastatic treatment
author_facet Shuyang S. Qin
Alexa D. Melucci
Alexander C. Chacon
Peter A. Prieto
author_sort Shuyang S. Qin
title Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care
title_short Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care
title_full Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care
title_fullStr Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care
title_full_unstemmed Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care
title_sort adoptive t cell therapy for solid tumors: pathway to personalized standard of care
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2021-04-01
description Adoptive cell therapy (ACT) with tumor-infiltrating T cells (TILs) has emerged as a promising therapy for the treatment of unresectable or metastatic solid tumors. One challenge to finding a universal anticancer treatment is the heterogeneity present between different tumors as a result of genetic instability associated with tumorigenesis. As the epitome of personalized medicine, TIL-ACT bypasses the issue of intertumoral heterogeneity by utilizing the patient’s existing antitumor immune response. Despite being one of the few therapies capable of inducing durable, complete tumor regression, many patients fail to respond. Recent research has focused on increasing therapeutic efficacy by refining various aspects of the TIL protocol, which includes the isolation, ex vivo expansion, and subsequent infusion of tumor specific lymphocytes. This review will explore how the therapy has evolved with time by highlighting various resistance mechanisms to TIL therapy and the novel strategies to overcome them.
topic adoptive cell therapy
tumor-infiltrating T cells
immunotherapy
metastatic treatment
url https://www.mdpi.com/2073-4409/10/4/808
work_keys_str_mv AT shuyangsqin adoptivetcelltherapyforsolidtumorspathwaytopersonalizedstandardofcare
AT alexadmelucci adoptivetcelltherapyforsolidtumorspathwaytopersonalizedstandardofcare
AT alexandercchacon adoptivetcelltherapyforsolidtumorspathwaytopersonalizedstandardofcare
AT peteraprieto adoptivetcelltherapyforsolidtumorspathwaytopersonalizedstandardofcare
_version_ 1721538843518173184

Similar Items